CLL: Venetoclax Combos Top First-Line Chemoimmunotherapy CLL: Venetoclax Combos Top First-Line Chemoimmunotherapy
A combination of venetoclax, ibrutinib, and obinutuzumab outperforms first-line chemoimmunotherapy for chronic lymphocytic leukemia in otherwise fit adults with few comorbidities.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 15, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
CLL: Black Patients Die Sooner Than White Patients CLL: Black Patients Die Sooner Than White Patients
Although Black patients are much less likely to develop chronic lymphocytic leukemia than are White patients, they are more likely to die sooner from the disease.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 11, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Venetoclax-Obinutuzumab With, Without Ibrutinib Superior in Leukemia
THURSDAY, May 11, 2023 -- For fit patients with chronic lymphocytic leukemia (CLL), venetoclax-obinutuzumab with or without ibrutinib, is superior to chemoimmunotherapy as first-line treatment, according to a study published in the May 11 issue of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 11, 2023 Category: Pharmaceuticals Source Type: news
Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies
HORSHAM, Pa., May 2, 2023 – Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies. These investigational CD20-directed autologous CAR-Ts have demonstrated promising overall and complete response rates in Phase 1 studies in patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL) in China, with the m...
Source: Johnson and Johnson - May 2, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Frontline CLL Therapy: Avoiding Adverse Events Frontline CLL Therapy: Avoiding Adverse Events
Second-generation Bruton ' s tyrosine kinase inhibitors are a great frontline option for most, if not all, patients with chronic lymphocytic leukemia (CLL), owing to their improved toxicity profiles.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 25, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Relapsed CLL: New Approaches Prolong Survival Relapsed CLL: New Approaches Prolong Survival
Experts discuss treatment options for patients with relapsed chronic lymphocytic leukemia.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 20, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
MRD: Powerful Metric for CLL Research MRD: Powerful Metric for CLL Research
The latest drugs for chronic lymphocytic leukemia (CLL) offer prolonged remission, along with a need for better tools to gauge their effectiveness: measurable residual disease (MRD) could be useful.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 7, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Update on IMBRUVICA ® (ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications
HORSHAM, Pa., April 6, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics, an AbbVie Company, announced today the intent to voluntarily withdraw the U.S. indications for IMBRUVICA® (ibrutinib) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, and for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. This decision was made in consultation with the U.S. Food and Drug Administration (FDA), c...
Source: Johnson and Johnson - April 6, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
CLL Treatment: More Infections Among Real-World Patients CLL Treatment: More Infections Among Real-World Patients
A high rate of severe infections was seen in patients with chronic lymphocytic leukemia (CLL) or B-cell lymphoma who were taking ibrutinib (Imbruvica), idelalisib (Zydelig), or venetoclax (Venclexta).MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 9, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Is the 'Golden Age' of Biotech Over?
(MedPage Today) -- MedPage Today spoke with former Forbes senior editor Nathan Vardi about his new book, For Blood and Money, which tells the "extreme" story of the development of two game-changing medications for chronic lymphocytic leukemia ... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - February 13, 2023 Category: American Health Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Basel, 2 February 2023Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLun...
Source: Roche Media News - February 2, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLunsumio (follicular lymp...
Source: Roche Investor Update - February 2, 2023 Category: Pharmaceuticals Source Type: news
Off Their Pricey CML Meds, Many Thrive Off Their Pricey CML Meds, Many Thrive
Over the last few years, physicians have experimented with taking patients with chronic myeloid leukemia (CML) off their drugs entirely, and the results are promising.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 26, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
FDA Approves New Drug for Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
MONDAY, Jan. 23, 2023 -- The U.S. Food and Drug Administration has approved zanubrutinib (Brukinsa), a next-generation BTK inhibitor, for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
The approval was... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 23, 2023 Category: General Medicine Source Type: news
FDA Approves Zanubrutinib (Brukinsa) for Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
MONDAY, Jan. 23, 2023 -- The U.S. Food and Drug Administration has approved zanubrutinib (Brukinsa), a next-generation BTK inhibitor, for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
The approval was... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 23, 2023 Category: General Medicine Source Type: news
